Didactics-PRESERVE-004/GOG Phase 2 Randomized dose optimization trial ot gotistobart

PRESERVE-004/GOG Phase 2 Randomized dose optimization trial ot gotistobart

Video Transcription

Video Summary

This presentation discusses a phase two trial assessing the safety and efficacy of Gotistibart, a pH-sensitive anti-CTLA4 antibody, combined with Pembrolizumab for platinum-resistant ovarian cancer. The trial indicated promising anti-tumor activity with response rates of 27.3% and 34.5% in different dosage groups. Despite patients being heavily pre-treated, the combination therapy was well-tolerated, with manageable safety profiles. The trial aims to establish an optimal dosage level and, if further analyses confirm these findings, this combination treatment may be explored in broader randomized settings for ovarian cancer.

Asset Subtitle

Joyce Barlin
March 2025

Keywords

Gotistibart

Pembrolizumab

ovarian cancer

clinical trial

anti-CTLA4 antibody